ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 10/28/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 28/10/2025

Benelux Morning Notes

Aedifica and Cofinimmo: Update about the deal. BAM Group: Preview - you have this and you have that. Basic-Fit: Investor call highlights Clever Fit acquisition. dsm-firmenich: Symrise 3Q25 results. KPN: Odido reduces fibre prices for higher speeds, increases prices for lower speeds. KPN: In line EBITDAal on lower revenues, guidance reiterated. Philips: 3Q25 preview, strong 4Q25 needed. Sif Group: Preview - boosting factory output and profit. Vastned: Strong progress on synergies, EPS and DPS guidance revised upward

Aedifica Pre-notification ends, approval within 55 business days

Yesterday evening, Aedifica announced it has ended the pre-notification phase in the competitive approval process for its merger with Cofinimmo. This phase had already been postponed for 1 month at the end of September. Now, the college of the BCA can make a decision for approval within 55 business days, longer than the initial 40 days we were expecting as remedies have been submitted. If this is approved, the prospectus is filed with the FSMA. The first exchange period can likely open in February 2026. Aedifica submitted remedies of EUR 300.0m in Belgium which is higher than we were expecting...

Autolus Aucatzyl phase 1 maintains SLE responses with longer follow up

Autolus announced that follow-up data from the ongoing phase 1 (CARLYSLE) dose confirmation trial of Aucatzyl (obe-cel, CD19 CAR-T) in severe refractory systemic lupus erythematosus (srSLE), will be presented during a poster session at the American College of Rheumatology Convergence 2025. The updated results demonstrate durability of outcomes observed in the initial readout (presented April 2025) over a longer follow up period as evidenced by the absence of new disease activity, no other lupus directed therapy required, and all patients achieving steroid tapering (=5mg/day). Autolus is well p...

Hyloris Signs agreement with Orion for Tranexamic Acid RTU in Europe

Hyloris announced that it has entered into an exclusive license and supply agreement with Orion for Tranexamic Acid Intravenous Premix RTU (TXA RTU) in major European markets. This follows a previously announced agreement with Avenacy in the US, though we note this product, being a generic, is non-core for the company, as Hyloris' main focus is on reformulation and repurposing via the 505(b)(2) pathway. The company has not disclosed specific figures under the agreement, however it will be eligible to receive milestones (we estimate a total amount of approx. € 1m) and revenue from product suppl...